Palvella Therapeutics (PVLA) Operating Leases (2019 - 2026)

Palvella Therapeutics (PVLA) has 7 years of Operating Leases data on file, last reported at $375000.0 in Q1 2026.

• Operating Leases for Q1 2026 came in at $375000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $375000.0 (changed N/A YoY), and the FY2025 annual result was $431000.0, changed N/A from the prior year.
• Operating Leases declined to $375000.0 in Q1 2026 per PVLA's latest filing, from $431000.0 in the prior quarter.
• Over five years, Operating Leases peaked at $13.4 million in Q1 2022 and troughed at $375000.0 in Q1 2026.
• A 4-year average of $9.6 million and a median of $12.5 million in 2022 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2022 and 2023: Operating Leases decreased 26.4% in 2022, then retreated 2.07% in 2023.
• A 4-year view of Operating Leases shows it stood at $12.2 million in 2022, then advanced by 4.76% to $12.8 million in 2023, then slumped by 96.64% to $431000.0 in 2025, then slipped by 12.99% to $375000.0 in 2026.
• Business Quant data shows PVLA's Operating Leases at $375000.0 in Q1 2026, $431000.0 in Q4 2025, and $12.8 million in Q2 2023.